Evidence map›Paper›PMID 34017323›Full record

ArticleFrontiers in immunology2021

The Effects of Tacrolimus on Tissue-Specific, Protein-Level Inflammatory Networks in Vascularized Composite Allotransplantation.

Ali Mubin Aral, Ruben Zamora, Derek Barclay, Jinling Yin, Fayten El-Dehaibi, Vasil E Erbas, Liwei Dong, Zhaoxiang Zhang, Huseyin Sahin, Vijay S Gorantla and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

Ali Mubin AralDepartment of Surgery, University of Pittsburgh, Pittsburgh, PA, United States.
Ruben ZamoraDepartment of Surgery, University of Pittsburgh, Pittsburgh, PA, United States.
Derek BarclayDepartment of Surgery, University of Pittsburgh, Pittsburgh, PA, United States.
Jinling YinDepartment of Surgery, University of Pittsburgh, Pittsburgh, PA, United States.
Fayten El-DehaibiDepartment of Surgery, University of Pittsburgh, Pittsburgh, PA, United States.
Vasil E ErbasDepartment of Plastic, Reconstructive and Aesthetic Surgery, Medicalpark Gaziantep Hospital, Gaziantep, Turkey.
Liwei DongPlastic and Aesthetic Surgery Department, XiJing Hospital, Xi'an, China.
Zhaoxiang ZhangPlastic and Aesthetic Surgery Department, XiJing Hospital, Xi'an, China.
Huseyin SahinPrivate Cagsu Hospital, Duzce, Turkey.
Vijay S GorantlaDepartment of Surgery, Wake Forest Institute for Regenerative Medicine, Wake Forest Baptist Medical Center, Winston Salem, NC, United States.
Yoram VodovotzDepartment of Surgery, University of Pittsburgh, Pittsburgh, PA, United States.
University of Pittsburgh · USXijing Hospital · CNForest Institute · USMcGowan Institute for Regenerative Medicine · USMedical Park Gaziantep Hospital · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Systems-level insights into inflammatory events after vascularized composite allotransplantation (VCA) are critical to the success of immunomodulatory strategies of these complex procedures. To date, the effects of tacrolimus (TAC) immunosuppression on inflammatory networks in VCA, such as in acute rejection (AR), have not been investigated. We used a systems biology approach to elucidate the effects of tacrolimus on dynamic networks and principal drivers of systemic inflammation in the context of dynamic tissue-specific immune responses following VCA. Lewis (LEW) rat recipients received orthotopic hind limb VCA from fully major histocompatibility complex-mismatched Brown Norway (BN) donors or matched LEW donors. Group 1 (syngeneic controls) received LEW limbs without TAC, and Group 2 (treatment group) received BN limbs with TAC. Time-dependent changes in 27 inflammatory mediators were analyzed in skin, muscle, and peripheral blood using Principal Component Analysis (PCA), Dynamic Bayesian Network (DyBN) inference, and Dynamic Network Analysis (DyNA) to define principal characteristics, central nodes, and putative feedback structures of systemic inflammation. Analyses were repeated on skin + muscle data to construct a "Virtual VCA", and in skin + muscle + peripheral blood data to construct a "Virtual Animal." PCA, DyBN, and DyNA results from individual tissues suggested important roles for leptin, VEGF, various chemokines, the NLRP3 inflammasome (IL-1β, IL-18), and IL-6 after TAC treatment. The chemokines MCP-1, MIP-1α; and IP-10 were associated with AR in controls. Statistical analysis suggested that 24/27 inflammatory mediators were altered significantly between control and TAC-treated rats in peripheral blood, skin, and/or muscle over time. "Virtual VCA" and "Virtual Animal" analyses implicated the skin as a key control point of dynamic inflammatory networks, whose connectivity/complexity over time exhibited a U-shaped trajectory and was mirrored in the systemic circulation. Our study defines the effects of TAC on complex spatiotemporal evolution of dynamic inflammation networks in VCA. We also demonstrate the potential utility of computational analyses to elucidate nonlinear, cross-tissue interactions. These approaches may help define precision medicine approaches to better personalize TAC immunosuppression in VCA recipients.

Indexed as

BiomarkersInflammation MediatorsVascularized Composite AllotransplantationAnimalsDisease Models, AnimalHindlimbImmunosuppressive AgentsInflammasomesModels, BiologicalOrgan SpecificityOrgan TransplantationRatsTacrolimusBiomarkersImmunosuppressive AgentsInflammasomesInflammation MediatorsTacrolimusacute rejectionimmunosuppressioninflammationnetwork analysissystems biologyvascularized composite allotransplantation

Identifiers

PMID34017323
PMCPMC8129572
OpenAlexW3158743824

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.